利用基因定序與生物資訊來發展精準醫療的商業模式

Abstract

近年來人類基因體資訊分析技術的快速發展讓我們了解到許多的疾病與基因突變有著密不可分的關係，諸多藥物之治療效果大多取決於病人的基因序列正常與否。時至今日，基因定序技術的進展快速及普及化，讓基因定序和個人化醫療在我們的生活中扮演越來越重要的角色，研究上也證實基因的損傷與變異與許多人類疾病的發生有著高度的相關性。因此，此新創公司的定位設定為基因資訊分析服務公司。我們使用最先進的軟硬體設備來提供專業的高通量基因定序資訊分析(high-throughput sequencing data analysis)、基因表現資訊分析(gene expression data analysis)、宏基因體學數據分析(Metagenomics analysis)、分子生物訊息傳遞路徑分析(Pathway analysis)與生物統計諮詢服務。公司團隊將使用以上技術來為客戶進行分析服務，並同時找尋可專利性的疾病基因分子生物標記，使其具有申請專利之潛力與高度市場價值。我們同步開發與臨床醫療需求息息相關的癌症風險評估基因檢測和標靶藥物用藥指引基因檢測，公司提供之癌症風險評估基因檢測和標靶藥物用藥指引基因檢測若能廣泛應用於臨床醫療，將可使醫師或相關醫護人員進行早期的癌症風險預測以及後續的癌症精準標靶藥物治療，並對台灣民眾的癌症預防及治療提供實質的貢獻。

In recent years, the development of human genome information analysis has allowed us to understand that many of the human diseases are strongly associated with genetic mutations. The therapeutic effects of many drugs are dependent on the patient's genetic sequences. Advances in sequencing technologies and the growing popularity of genomic sequencing play an important role in the era of personalized medicine nowadays. Therefore, the new company provides genomic data analysis services. We use the most advanced software and hardware equipment to provide professional genomic sequencing data analysis, including high-throughput sequencing data analysis, gene expression data analysis, metagenomics analysis, molecular pathway analysis and bioinformatics consulting services. We use genomic data analysis technologies and statistical tools to look for potential genetic biomarkers associated with human diseases and provide evaluation for cancer-risk assessment and targeted therapy. Also, we plan to develop cancer-risk prediction assessment and cancer targeted drug screening services. These two services aim to provide accurate cancer-risk prediction and targeted drug screening results for clinical usage.